Gökhan Koca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gökhan Koca has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Meliha Korkmaz
University of Health Sciences, Ankara Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey
21 shared publications - Aylin Akbulut
University of Health Sciences, Ankara Training and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey
18 shared publications Meliha Korkmaz
Department of Nuclear Medicine, Ankara Training and Application Hospital, University of Health Sciences, Ankara, Turkey
16 shared publications- Nihat Yumuşak
Department of Pathology, Harran University, Faculty of Veterinary Medicine
14 shared publications - Koray Demirel
Department of Nuclear Medicine, Ankara Training and Research Hospital, University of Health Sciences, Ankara, Turkey
12 shared publications Koray Demirel
Department of Nuclear Medicine, Ministry of Health Ankara Training and Research Hospital Ankara
10 shared publications
Latest Publications
- 28 September 2026
- Published by Springer Nature in Clinical Rheumatology
- p. 1-13
Dose-dependent histopathological and immunohistochemical effects of metformin in experimental osteoarthritis
Objective To evaluate the dose-dependent effects of metformin on joint pathology and inflammatory and apoptotic processes in a monosodium iodoacetate (MIA)-induced rat model of osteoarthritis. Methods Forty male Wistar albino rats were randomized into four groups (n = 10): sham control, OA, MIA + metformin 100 mg/kg, and MIA + metformin 200 mg/kg. OA was induced by intra-articular injection of 3.5 mg MIA. Metformin was administered intraperitoneally for 30 days. Spontaneous pain-related behavior was scored with a semi-quantitative, non-reflexive system. Histopathological parameters and IL-1β, IL-6, TNF-α, caspase-3, and LC3 expression were examined. Results Compared with control, the OA group worsened across all histopathological parameters (p < 0.01). Immunohistochemically, IL-1β, IL-6, TNF-α, and caspase-3 expression increased, whereas LC3 expression decreased (p < 0.01). Histopathological severity and marker profiles changed in an ordered manner across the untreated OA and both metformin groups (Jonckheere-Terpstra, two-sided p < 0.001). After adjustment for six pairwise comparisons, the 200 mg/kg group differed from untreated OA on every tissue parameter, whereas the 100 mg/kg group did not reach the adjusted threshold for histopathology despite large effect sizes (Cliff’s delta 0.85 to 1.00). Pain-related behavior improved from day 3 to day 30 in both metformin groups (100 mg/kg: p = 0.005; 200 mg/kg: p = 0.028), whereas at day 30 only the 200 mg/kg group differed from untreated OA (adjusted p = 0.002). Conclusions Metformin showed chondroprotective and anti-inflammatory effects with reduced apoptotic marker expression and altered autophagy-related signaling, attenuating cartilage degeneration in a dose-dependent manner. Improvement in pain-related behavior compared with untreated OA was significant only at 200 mg/kg. Key Points • Metformin started on the day of MIA induction attenuated structural joint damage at day 30. • Histopathological and immunohistochemical outcomes showed an ordered dose-related pattern across untreated OA, 100 mg/kg, and 200 mg/kg groups. • Treatment was accompanied by reduced inflammatory and apoptotic marker expression and altered autophagy-related signaling. • At day 30, improvement in pain-related behavior was significant compared with untreated OA only at 200 mg/kg.
- 28 September 2026
- Published by Springer Nature in Clinical Rheumatology
- p. 1-13
Dose-dependent histopathological and immunohistochemical effects of metformin in experimental osteoarthritis
Objective To evaluate the dose-dependent effects of metformin on joint pathology and inflammatory and apoptotic processes in a monosodium iodoacetate (MIA)-induced rat model of osteoarthritis. Methods Forty male Wistar albino rats were randomized into four groups (n = 10): sham control, OA, MIA + metformin 100 mg/kg, and MIA + metformin 200 mg/kg. OA was induced by intra-articular injection of 3.5 mg MIA. Metformin was administered intraperitoneally for 30 days. Spontaneous pain-related behavior was scored with a semi-quantitative, non-reflexive system. Histopathological parameters and IL-1β, IL-6, TNF-α, caspase-3, and LC3 expression were examined. Results Compared with control, the OA group worsened across all histopathological parameters (p < 0.01). Immunohistochemically, IL-1β, IL-6, TNF-α, and caspase-3 expression increased, whereas LC3 expression decreased (p < 0.01). Histopathological severity and marker profiles changed in an ordered manner across the untreated OA and both metformin groups (Jonckheere-Terpstra, two-sided p < 0.001). After adjustment for six pairwise comparisons, the 200 mg/kg group differed from untreated OA on every tissue parameter, whereas the 100 mg/kg group did not reach the adjusted threshold for histopathology despite large effect sizes (Cliff’s delta 0.85 to 1.00). Pain-related behavior improved from day 3 to day 30 in both metformin groups (100 mg/kg: p = 0.005; 200 mg/kg: p = 0.028), whereas at day 30 only the 200 mg/kg group differed from untreated OA (adjusted p = 0.002). Conclusions Metformin showed chondroprotective and anti-inflammatory effects with reduced apoptotic marker expression and altered autophagy-related signaling, attenuating cartilage degeneration in a dose-dependent manner. Improvement in pain-related behavior compared with untreated OA was significant only at 200 mg/kg. Key Points • Metformin started on the day of MIA induction attenuated structural joint damage at day 30. • Histopathological and immunohistochemical outcomes showed an ordered dose-related pattern across untreated OA, 100 mg/kg, and 200 mg/kg groups. • Treatment was accompanied by reduced inflammatory and apoptotic marker expression and altered autophagy-related signaling. • At day 30, improvement in pain-related behavior was significant compared with untreated OA only at 200 mg/kg.
- 19 September 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (11) , 4903-4917
Platelet-Rich Plasma and Tadalafil Pretreatment Enhance Survival of Random-Pattern Skin Flaps in Rats
- 19 September 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (11) , 4903-4917
Platelet-Rich Plasma and Tadalafil Pretreatment Enhance Survival of Random-Pattern Skin Flaps in Rats
- 9 January 2026
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (4) , 406-412
Can Saccharomyces boulardii protect against radioactive iodine induced gastrointestinal damage? Study in a rat model
Radioactive iodine (RAI) is widely used for the diagnosis and treatment of thyroid diseases. Common side effects of RAI include sialadenitis, xerostomia and gastrointestinal symptoms. In this study we aimed to investigate the effect of Saccharomyces boulardii (S.boulardii) on the gastrointestinal changes induced by RAI. Twenty four Wistar albino rats were grouped into three; the first group received RAI, the second group received RAI together with S.boulardii (RAI-S) and the third group served as controls. Tissue oxidative stress parameters and zonulin levels-as a marker of increased intestinal permeability- were measured at the end of the study. The gastrointestinal tissue specimens are also microscopically analyzed and graded according to the Histological Activity Index (HAI). We found no difference in the zonulin levels. We detected no difference in oxidative stress parameters in most of the tissues except slight changes in duodenum and ileum. HAI scores were significantly lower in RAI-S group when compared to the RAI group. This study showed that S.boulardii is protective against RAI induced gastrointestinal damage. This effect is probably beyond its antioxidant properties or impacts on intestinal permeability.
- 9 January 2026
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 102 (4) , 406-412
Can Saccharomyces boulardii protect against radioactive iodine induced gastrointestinal damage? Study in a rat model
Radioactive iodine (RAI) is widely used for the diagnosis and treatment of thyroid diseases. Common side effects of RAI include sialadenitis, xerostomia and gastrointestinal symptoms. In this study we aimed to investigate the effect of Saccharomyces boulardii (S.boulardii) on the gastrointestinal changes induced by RAI. Twenty four Wistar albino rats were grouped into three; the first group received RAI, the second group received RAI together with S.boulardii (RAI-S) and the third group served as controls. Tissue oxidative stress parameters and zonulin levels-as a marker of increased intestinal permeability- were measured at the end of the study. The gastrointestinal tissue specimens are also microscopically analyzed and graded according to the Histological Activity Index (HAI). We found no difference in the zonulin levels. We detected no difference in oxidative stress parameters in most of the tissues except slight changes in duodenum and ileum. HAI scores were significantly lower in RAI-S group when compared to the RAI group. This study showed that S.boulardii is protective against RAI induced gastrointestinal damage. This effect is probably beyond its antioxidant properties or impacts on intestinal permeability.
- 2 January 2026
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 45 (3) , 500278
Superior vena cava syndrome as a manifestation of primary atypical carcinoid tumor of mediastinum by [68Ga]Ga-DOTA-TATE PET/CT
- 2 January 2026
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 45 (3) , 500278
Superior vena cava syndrome as a manifestation of primary atypical carcinoid tumor of mediastinum by [68Ga]Ga-DOTA-TATE PET/CT
- 23 October 2025
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 60 (4) , 1-3
Superior Vena Cava Syndrome in Medullary Thyroid Carcinoma Detected with 18F-FDG PET/CT; an Extremely Rare Complication
- 23 October 2025
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 60 (4) , 1-3
Superior Vena Cava Syndrome in Medullary Thyroid Carcinoma Detected with 18F-FDG PET/CT; an Extremely Rare Complication
- 22 September 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (12) , 3406-3417
Protective Role of Vitamin D in Attenuating RAI-Induced Liver Injury in Rats
- 22 September 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (12) , 3406-3417
Protective Role of Vitamin D in Attenuating RAI-Induced Liver Injury in Rats
- 10 July 2025
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 59 (6) , 482-483
Solitary Axillary Lymph Node Metastasis in Gastric Adenocarcinoma: A Staging PET/CT Surprise
- 10 July 2025
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 59 (6) , 482-483
Solitary Axillary Lymph Node Metastasis in Gastric Adenocarcinoma: A Staging PET/CT Surprise
- Open Access
- 18 November 2024
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 18 (6) , 367-372
Role of Ultrasonography and Dynamic Renal Scintigraphy Parameters in Decision Making Regarding Performance of Pyeloplasty in Children with Ureteropelvic Junction Obstruction
Amaç: Üreteropelvik bileşke darlığı (UPD) olan hastalarda cerrahi tedavinin zamanı konusunda çelişkili sonuçlar bulunmaktadır. Bu nedenle UPD tanı ve tedavisinde ultrasonografi (USG) ve dinamik böbrek sintigrafisi parametrelerinin öngörücü gücünü karşılaştırmayı amaçladık.Gereç ve Yöntemler: 2015-2020 yılları arasında UPD tanısı alan hastalar geriye dönük olarak değerlendirildi, diğer konjenital üriner anomaliler dışlandı. Renal pelvis ön-arka çapı USG ile değerlendirildi ve Fetal Üroloji Derneği’nin derecelendirme sistemine göre evrelendi. Dinamik böbrek sintigrafisinde maksimum böbrek aktivitesine ulaşma süresi (Tmax), maksimum aktivitenin yarısının temizlenmesine kadar geçen süre (T1/2), diferansiyel böbrek fonksiyonu ve diüretik yanıtı kaydedildi.Bulgular: Çalışmaya 59 hasta dahil edildi. Elli dokuz hastanın 13’üne (%22) piyeloplasti yapıldı Piyeloplasti grubunda (%22) piyeloplasti yapılmayan gruba göre yüksek dereceli hidronefroz tesbit edildi ve bu grupta renal pelvis ön-arka çapı daha fazlaydı. Ayrıca piyeloplasti grubunda Tmax ve T1/2 değerleri piyeloplasti yapılmayan gruba göre anlamlı derecede daha uzundu (p
- 18 November 2024
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 18 (6) , 367-372
Open AccessRole of Ultrasonography and Dynamic Renal Scintigraphy Parameters in Decision Making Regarding Performance of Pyeloplasty in Children with Ureteropelvic Junction Obstruction
Amaç: Üreteropelvik bileşke darlığı (UPD) olan hastalarda cerrahi tedavinin zamanı konusunda çelişkili sonuçlar bulunmaktadır. Bu nedenle UPD tanı ve tedavisinde ultrasonografi (USG) ve dinamik böbrek sintigrafisi parametrelerinin öngörücü gücünü karşılaştırmayı amaçladık.Gereç ve Yöntemler: 2015-2020 yılları arasında UPD tanısı alan hastalar geriye dönük olarak değerlendirildi, diğer konjenital üriner anomaliler dışlandı. Renal pelvis ön-arka çapı USG ile değerlendirildi ve Fetal Üroloji Derneği’nin derecelendirme sistemine göre evrelendi. Dinamik böbrek sintigrafisinde maksimum böbrek aktivitesine ulaşma süresi (Tmax), maksimum aktivitenin yarısının temizlenmesine kadar geçen süre (T1/2), diferansiyel böbrek fonksiyonu ve diüretik yanıtı kaydedildi.Bulgular: Çalışmaya 59 hasta dahil edildi. Elli dokuz hastanın 13’üne (%22) piyeloplasti yapıldı Piyeloplasti grubunda (%22) piyeloplasti yapılmayan gruba göre yüksek dereceli hidronefroz tesbit edildi ve bu grupta renal pelvis ön-arka çapı daha fazlaydı. Ayrıca piyeloplasti grubunda Tmax ve T1/2 değerleri piyeloplasti yapılmayan gruba göre anlamlı derecede daha uzundu (p
- 27 February 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 44 (1) , 1-12
The influencer effect of Dexmedetomidine on radioiodine relevant to lacrimal gland impairment
Purpose To assess the potential influencing effects of Dexmedetomidine on impaired lacrimal glands after high-dose radioiodine treatment (RAI). Methods Thirty-six rats were arbitrarily separated into 3 groups: Sham, RAI, and Dexmedetomidine. Dexmedetomidine group was given Dexmedetomidine and RAI, the Sham group was given the same millimeters of saline, and the RAI group was given RAI only. All forms of lacrimal glands, including harderian glands (HG), extraorbital (EG), and intraorbital (IG) lacrimal glands, were evaluated for immunohistochemical, histopathologic assessments and also for tissue cytokines, oxidant and antioxidant levels. Results Dexmedetomidine significantly ameliorated histopathologic changes such as periacinar fibrosis, acinar atrophy, lymphocytic infiltration, ductal proliferation, lipofuscin-like accumulation, and nucleus changes caused by RAI in all lacrimal gland forms (p < 0.05 for all of the parameters). However, periductal fibrosis was improved significantly only in EG (p = 0.049), and mast cell infiltration was improved significantly only in IG (p = 0.038) in Dexmedetomidine groups. There was a significant decrease in the elevated caspase-3 and TUNEL levels after RAI administration in the Dexmedetomidine group in all lacrimal gland forms (p < 0.05 for all parameters). Dexmedetomidine attenuated NF-kb, TNF-α, and IL-6 levels significantly diminished total oxidant status and raised total antioxidant status levels (p < 0.05 for all parameters). Conclusions The results of this study demonstrated that following RAI, Dexmedetomidine diminished inflammation, tissue cytokine levels, and apoptosis and ameliorated impaired histopathologic patterns of the lacrimal glands.
- 27 February 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 44 (1) , 1-12
The influencer effect of Dexmedetomidine on radioiodine relevant to lacrimal gland impairment
Purpose To assess the potential influencing effects of Dexmedetomidine on impaired lacrimal glands after high-dose radioiodine treatment (RAI). Methods Thirty-six rats were arbitrarily separated into 3 groups: Sham, RAI, and Dexmedetomidine. Dexmedetomidine group was given Dexmedetomidine and RAI, the Sham group was given the same millimeters of saline, and the RAI group was given RAI only. All forms of lacrimal glands, including harderian glands (HG), extraorbital (EG), and intraorbital (IG) lacrimal glands, were evaluated for immunohistochemical, histopathologic assessments and also for tissue cytokines, oxidant and antioxidant levels. Results Dexmedetomidine significantly ameliorated histopathologic changes such as periacinar fibrosis, acinar atrophy, lymphocytic infiltration, ductal proliferation, lipofuscin-like accumulation, and nucleus changes caused by RAI in all lacrimal gland forms (p < 0.05 for all of the parameters). However, periductal fibrosis was improved significantly only in EG (p = 0.049), and mast cell infiltration was improved significantly only in IG (p = 0.038) in Dexmedetomidine groups. There was a significant decrease in the elevated caspase-3 and TUNEL levels after RAI administration in the Dexmedetomidine group in all lacrimal gland forms (p < 0.05 for all parameters). Dexmedetomidine attenuated NF-kb, TNF-α, and IL-6 levels significantly diminished total oxidant status and raised total antioxidant status levels (p < 0.05 for all parameters). Conclusions The results of this study demonstrated that following RAI, Dexmedetomidine diminished inflammation, tissue cytokine levels, and apoptosis and ameliorated impaired histopathologic patterns of the lacrimal glands.